Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claude Becker

Showing results (71-80 of 93) with videos related to

Pageof 10
Sort By:
Arthritis and Rheumatism|December 4, 2010
Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trialPhilip Mease, Mark C Genovese, Geoffrey Gladstein, et al.
Annals of the Rheumatic Diseases|September 15, 2011
Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST StudyMichael Schiff, Mauro Keiserman, Christine Codding, et al.
The New England Journal of Medicine|September 16, 2005
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibitionMark C Genovese, Jean-Claude Becker, Michael Schiff, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 12, 2018
Partial maintenance of organ-specific epigenetic marks during plant asexual reproduction leads to heritable phenotypic variationAnjar Wibowo, Claude Becker, Julius Durr, et al.
British Journal of Clinical Pharmacology|August 18, 2016
Comparative assessment of clinical response in patients with rheumatoid arthritis between PF-05280586, a proposed rituximab biosimilar, and rituximabJason H Williams, Matthew M Hutmacher, Matthew L Zierhut, et al.
Annals of the Rheumatic Diseases|January 1, 2015
Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosisRene Westhovens, Manuel Robles, Antonio Carlos Ximenes, et al.
The Plant Cell|November 5, 2015
Plants Release Precursors of Histone Deacetylase Inhibitors to Suppress Growth of CompetitorsSascha Venturelli, Regina G Belz, Andreas Kämper, et al.
The New England Journal of Medicine|November 14, 2003
Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4IgJoel M Kremer, Rene Westhovens, Marc Leon, et al.
Plos Genetics|February 13, 2018
The rate and potential relevance of new mutations in a colonizing plant lineageMoises Exposito-Alonso, Claude Becker, Verena J Schuenemann, et al.
Nature|January 13, 2022
Mutation bias reflects natural selection in Arabidopsis thalianaJ Grey Monroe, Thanvi Srikant, Pablo Carbonell-Bejerano, et al.
Pageof 10

Showing results (71-80 of 93) with videos related to

Sort By:
Pageof 10
Arthritis and Rheumatism|December 4, 2010
Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trialPhilip Mease, Mark C Genovese, Geoffrey Gladstein, et al.
Annals of the Rheumatic Diseases|September 15, 2011
Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST StudyMichael Schiff, Mauro Keiserman, Christine Codding, et al.
The New England Journal of Medicine|September 16, 2005
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibitionMark C Genovese, Jean-Claude Becker, Michael Schiff, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 12, 2018
Partial maintenance of organ-specific epigenetic marks during plant asexual reproduction leads to heritable phenotypic variationAnjar Wibowo, Claude Becker, Julius Durr, et al.
British Journal of Clinical Pharmacology|August 18, 2016
Comparative assessment of clinical response in patients with rheumatoid arthritis between PF-05280586, a proposed rituximab biosimilar, and rituximabJason H Williams, Matthew M Hutmacher, Matthew L Zierhut, et al.
Annals of the Rheumatic Diseases|January 1, 2015
Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosisRene Westhovens, Manuel Robles, Antonio Carlos Ximenes, et al.
The Plant Cell|November 5, 2015
Plants Release Precursors of Histone Deacetylase Inhibitors to Suppress Growth of CompetitorsSascha Venturelli, Regina G Belz, Andreas Kämper, et al.
The New England Journal of Medicine|November 14, 2003
Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4IgJoel M Kremer, Rene Westhovens, Marc Leon, et al.
Plos Genetics|February 13, 2018
The rate and potential relevance of new mutations in a colonizing plant lineageMoises Exposito-Alonso, Claude Becker, Verena J Schuenemann, et al.
Nature|January 13, 2022
Mutation bias reflects natural selection in Arabidopsis thalianaJ Grey Monroe, Thanvi Srikant, Pablo Carbonell-Bejerano, et al.
Pageof 10